Allogeneic hematopoietic cell transplantation; the current renaissance

Area of Science:

• Hematology
• Transplantation Immunology
• Oncology

Background:

• Allogeneic hematopoietic cell transplantation (HCT) is a curative option for various hematologic malignancies and nonmalignant disorders.
• Significant progress has been made in HCT, enhancing its safety and applicability across diverse patient populations.
• Relapse post-HCT remains a primary challenge, impacting long-term patient survival.

Purpose of the Study:

• To review recent advancements in allogeneic HCT.
• To discuss the expanded role of HCT in managing hematologic disorders.
• To highlight strategies for mitigating relapse after HCT.

Main Methods:

• Review of recent literature on allogeneic HCT.
• Analysis of improvements in candidate selection and risk stratification.
• Evaluation of novel therapeutic agents used in conjunction with HCT.

Main Results:

• Improved outcomes and expanded indications for HCT due to advances in candidate selection, safety, and supportive care.
• Increased utilization of HCT in older patients and with alternative donors.
• Emergence of targeted and immunotherapeutic agents to combat relapse.

Conclusions:

• Allogeneic HCT has evolved significantly, offering improved survival for patients with hematologic disorders.
• The integration of novel anti-cancer and immunotherapeutic agents holds promise for further reducing relapse rates.
• Future directions emphasize combining HCT with advanced therapies to optimize cure rates and long-term outcomes.